A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer - PubMed
2 hours ago
- #nanobody-drug-conjugate
- #pancreatic-cancer
- #bispecific-ADC
- Development of B6ADC, a bispecific nanobody-drug conjugate targeting TROP2 and c-Met for pancreatic cancer treatment.
- B6ADC shows potent cytotoxicity in vitro and superior tumor inhibition in vivo compared to single-target ADCs.
- Effective at low concentration (2.2 mg/kg) with single-dose efficacy, even against large tumors.
- Improves selectivity for tumors with dual or weakly positive antigen expression.
- Potential broad-spectrum antitumor activity for pancreatic cancer and other TROP2/c-Met-expressing malignancies.